Bone News and Research

RSS

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Study finds occurrence of low BMD in inflammatory bowel disease patients

A thesis from the University of Gothenburg (Sweden) is the first in Scandinavia to study the occurrence of low bone mineral density in children and teenagers with inflammatory bowel disease. Half of the patients in the study showed signs of low bone mineral density.

23 Aug 2010

Early year-round sports specialization contributes to rise of overuse injuries

Bobby Boyle engages in serious year-round sports training and has had his share of minor muscle injuries. When the 12-year-old athlete felt tightness in the back of his thigh while sprinting at track practice, he and his parents thought he pulled a hamstring and assumed it would heal with limited exercise time.

21 Aug 2010

Whole body MRI may help to diagnose suspected child abuse: Study

Whole-body magnetic resonance imaging (MRI), which is highly accurate at detecting soft-tissue abnormalities, may serve a role in detecting suspected child abuse in infants, according to a study in the September issue of the American Journal of Roentgenology.

21 Aug 2010

Causes and consequences of increased adiposity and decreased muscle and bone mass

Increased adiposity and decreased muscle mass contribute substantially to age-dependent disease and disability. In particular age-related increase in adiposity is quickly becoming a major threat to public health throughout the world. Although the hypothesis that age-related changes in body composition are due to lifestyle choices alone is well accepted, it is a vast oversimplification.

20 Aug 2010

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.

20 Aug 2010

Even low-level exposure to cigarette smoke affects gene function in lungs

Casual smokers may think that smoking a few cigarettes a week is "no big deal." But according to new research from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, having an infrequent smoke, or being exposed to secondhand smoke, may be doing more harm than people may think. The findings may further support public smoking bans, say the authors.

20 Aug 2010

Benvenue Medical enrolls first patient in landmark KAST trial

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has enrolled the first patient into the landmark KAST (Kiva® System as a Vertebral Augmentation Treatment - A Safety and Effectiveness Trial) study. The case was performed by Sean Tutton, MD FSIR, Associate Professor of Radiology and Surgery at the Medical College of Wisconsin in Milwaukee.

20 Aug 2010

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

MicroAire acquires Endotine fixation systems for facial aesthetic surgery

MicroAire Surgical Instruments is pleased to announce the acquisition of Endotine® bioabsorbable, multi-point, soft-tissue fixation systems for facial aesthetic surgery.

20 Aug 2010

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.

20 Aug 2010

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Due to overwhelming response from researchers, a second round of abstract submissions for the upcoming 2nd International Symposium on MR-guided Focused Ultrasound will open on Monday, August 23, 2010, nine days earlier than previously announced. The submission deadline will be moved forward to Monday, September 6, 2010.

19 Aug 2010

Study finds no clinical benefits from gender-specific total knee prostheses for women

A gender-specific total knee prosthesis was developed to more closely match the anatomy of the female knee, aiming to be a better fit resulting in better outcomes for women. However, a recent study in the Journal of Bone and Joint Surgery (JBJS) found that 85 women who received a gender-specific implant in one knee and a standard prosthesis in the other knee found no clinical benefits of the gender-specific knee.

19 Aug 2010

Treatment with DMARDs reduces rheumatoid arthritis disability: Study

For people living with rheumatoid arthritis (RA), the level of disease activity measured using the standard DAS 28 score is the factor most strongly affecting the level of RA-related disability, according to a study in Journal of Clinical Rheumatology.

19 Aug 2010

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

19 Aug 2010

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Researchers have developed an improved coating technique that could strengthen the connection between titanium joint-replacement implants and a patients' own bone. The stronger connection created by manipulating signals the body's own cells use to encourage growth could allow the implants to last longer.

19 Aug 2010

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).

18 Aug 2010

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

Wound Management Technologies, Inc. announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists.

18 Aug 2010

RTI, Medtronic take several steps to continuously improve their relationship

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, in response to inquiries regarding Medtronic's announced acquisition of Osteotech stated today that the relationship between Medtronic and RTI Biologics continues to be strong, with no changes near-term.

18 Aug 2010

Bone News and Research

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Study finds occurrence of low BMD in inflammatory bowel disease patients

Early year-round sports specialization contributes to rise of overuse injuries

Whole body MRI may help to diagnose suspected child abuse: Study

Causes and consequences of increased adiposity and decreased muscle and bone mass

Tasigna receives approval for chronic myeloid leukemia in Canada

Even low-level exposure to cigarette smoke affects gene function in lungs

Benvenue Medical enrolls first patient in landmark KAST trial

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

MicroAire acquires Endotine fixation systems for facial aesthetic surgery

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

Second round of abstract submission for International Symposium on MR-guided Focused Ultrasound

Study finds no clinical benefits from gender-specific total knee prostheses for women

Treatment with DMARDs reduces rheumatoid arthritis disability: Study

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

RTI, Medtronic take several steps to continuously improve their relationship

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News